We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+48.18%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$2.05B
AUM Growth
+$632M
Cap. Flow
+$113M
Cap. Flow %
5.52%
Top 10 Hldgs %
58.91%
Holding
40
New
7
Increased
9
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$58.5M
2
SLNO
Soleno Therapeutics
SLNO
+$54.9M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$38.4M
4
TERN
Terns Pharmaceuticals
TERN
+$36.4M
5
LBRX
LB Pharmaceuticals
LBRX
+$23.8M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$51.4M
2
CDTX
Cidara Therapeutics
CDTX
+$37.6M
3
VRDN icon
Viridian Therapeutics
VRDN
+$30.2M
4
VERA icon
Vera Therapeutics
VERA
+$18.8M
5
DFTX
Definium Therapeutics
DFTX
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$332M 16.2%
3,525,000
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$121M 5.91%
1,400,000
+25,000
+2% +$1.98M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.32B
$108M 5.29%
2,700,000
-325,000
-11% -$11.4M
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$104M 5.08%
7,250,000
+4,938,836
+214% +$58.5M
ELVN icon
5
Enliven Therapeutics
ELVN
$3.78B
$96.1M 4.69%
4,692,809
– –
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.16B
$93.9M 4.58%
2,338,287
+13,287
+0.6% +$500K
ALKS icon
7
Alkermes
ALKS
$8.82B
$92.9M 4.54%
3,096,754
+646,754
+26% +$18.2M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$91.3M 4.46%
1,350,000
+740,000
+121% +$54.9M
RLAY icon
9
Relay Therapeutics
RLAY
$4.02B
$88.7M 4.33%
17,000,000
+3,650,000
+27% +$13.9M
CLDX icon
10
Celldex Therapeutics
CLDX
$2.77B
$78.3M 3.82%
3,028,335
-421,665
-12% -$9.77M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$69.1M 3.37%
2,850,000
-448,289
-14% -$7.97M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.13B
$69.1M 3.37%
3,200,000
-1,675,000
-34% -$30.2M
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.75B
$68.1M 3.32%
1,025,000
-50,000
-5% -$2.84M
PHVS icon
14
Pharvaris
PHVS
$2.39B
$60.3M 2.95%
2,418,476
+507,043
+27% +$11.2M
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
$56M 2.73%
585,000
-590,000
-50% -$37.6M
AMLX icon
16
Amylyx Pharmaceuticals
AMLX
$2.05B
$55.4M 2.7%
+4,075,478
New +$38.4M
TYRA icon
17
Tyra Biosciences
TYRA
$1.82B
$47.2M 2.31%
3,375,000
+275,000
+9% +$3.14M
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$42.8M 2.09%
+5,700,000
New +$36.4M
KYMR icon
19
Kymera Therapeutics
KYMR
$9.1B
$42.5M 2.07%
750,000
– –
DFTX
20
Definium Therapeutics
DFTX
$5.73B
$38M 1.86%
3,225,000
-1,775,000
-36% -$16.6M
NRIX icon
21
Nurix Therapeutics
NRIX
$2.43B
$34.9M 1.71%
3,780,055
-168,598
-4% -$1.75M
ORKA
22
Oruka Therapeutics
ORKA
$5.56B
$33.7M 1.65%
1,753,054
+333,340
+23% +$4.94M
SYRE icon
23
Spyre Therapeutics
SYRE
$8.87B
$33.3M 1.63%
1,988,084
– –
DRUG
24
Bright Minds Biosciences
DRUG
$700M
$30.3M 1.48%
500,000
– –
ASMB icon
25
Assembly Biosciences
ASMB
$506M
$25.6M 1.25%
+1,000,000
New +$21.9M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Commodore Capital held 40 positions worth $2.05B, up 45% from $1.42B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Commodore Capital deployed $113M of net new capital in Q3 2025, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 4,075,478 shares worth $55.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cidara Therapeutics, an estimated $37.6M trimmed.

  • Commodore Capital's largest Q3 2025 buy was Amylyx Pharmaceuticals: 4,075,478 shares worth $55.4M.
  • Commodore Capital added most to Cogent Biosciences in Q3 2025, an estimated $58.5M increase.
  • Commodore Capital's biggest Q3 2025 reduction was Cidara Therapeutics, cutting an estimated $37.6M.
  • Commodore Capital fully exited Scholar Rock in Q3 2025, selling an estimated $51.4M.
  • Commodore Capital's ten largest holdings make up 59% of its $2.05B portfolio in Q3 2025.
  • Commodore Capital opened 7 new positions and closed 3 in Q3 2025.
  • Commodore Capital's portfolio value rose 45% quarter-over-quarter to $2.05B.

Based on Commodore Capital's 13F filing for Q3 2025, filed 14 Nov 2025.